KR101720961B1 - 다능성 세포의 분화 - Google Patents

다능성 세포의 분화 Download PDF

Info

Publication number
KR101720961B1
KR101720961B1 KR1020117022315A KR20117022315A KR101720961B1 KR 101720961 B1 KR101720961 B1 KR 101720961B1 KR 1020117022315 A KR1020117022315 A KR 1020117022315A KR 20117022315 A KR20117022315 A KR 20117022315A KR 101720961 B1 KR101720961 B1 KR 101720961B1
Authority
KR
South Korea
Prior art keywords
cells
differentiation
delete delete
medium
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117022315A
Other languages
English (en)
Korean (ko)
Other versions
KR20110122858A (ko
Inventor
디피카 라제쉬
레이첼 루이스
Original Assignee
셀룰러 다이내믹스 인터내셔널, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 filed Critical 셀룰러 다이내믹스 인터내셔널, 인코포레이티드
Publication of KR20110122858A publication Critical patent/KR20110122858A/ko
Application granted granted Critical
Publication of KR101720961B1 publication Critical patent/KR101720961B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020117022315A 2009-02-27 2010-03-01 다능성 세포의 분화 Active KR101720961B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15630409P 2009-02-27 2009-02-27
US61/156,304 2009-02-27
PCT/US2010/025776 WO2010099539A1 (en) 2009-02-27 2010-03-01 Differentiation of pluripotent cells

Publications (2)

Publication Number Publication Date
KR20110122858A KR20110122858A (ko) 2011-11-11
KR101720961B1 true KR101720961B1 (ko) 2017-03-29

Family

ID=42097524

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117022315A Active KR101720961B1 (ko) 2009-02-27 2010-03-01 다능성 세포의 분화

Country Status (9)

Country Link
US (2) US8372642B2 (enExample)
EP (1) EP2401364B1 (enExample)
JP (2) JP5816100B2 (enExample)
KR (1) KR101720961B1 (enExample)
CN (1) CN102388130B (enExample)
AU (1) AU2010217739B2 (enExample)
CA (1) CA2753679C (enExample)
IL (1) IL214818A (enExample)
WO (1) WO2010099539A1 (enExample)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102230288B1 (ko) 2006-04-14 2021-03-22 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
JP5804280B2 (ja) * 2009-09-08 2015-11-04 国立大学法人京都大学 多能性幹細胞からの肥満細胞の製造方法
ES2779048T3 (es) 2009-11-12 2020-08-13 Technion Res & Dev Foundation Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en un estado indiferenciado
US8703487B2 (en) * 2009-12-01 2014-04-22 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
CA3095576A1 (en) * 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
EP2539437B1 (en) 2010-02-25 2017-08-02 The Johns Hopkins University SMOOTH MUSCLE-LIKE CELLS (SMLCs) DERIVED FROM HUMAN PLURIPOTENT STEM CELLS
CA2802249A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
EP2601289B1 (en) 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
EP2615165B1 (en) 2010-09-10 2016-08-03 The University of Tokyo Culture method related to differentiation of pluripotent stem cells into blood cells
WO2012103098A2 (en) * 2011-01-24 2012-08-02 Immunepath, Inc. Compositions and methods for treating hematological cytopenias
JP6148429B2 (ja) * 2011-01-31 2017-06-14 協和発酵バイオ株式会社 ヒト多能性幹細胞の培養方法
US9574179B2 (en) * 2011-02-08 2017-02-21 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
CN102161980B (zh) * 2011-02-12 2013-07-31 浙江大学 用人间充质干细胞为滋养层培养诱导多能干细胞的方法
US9499789B2 (en) 2011-02-23 2016-11-22 Kyoto University Method for producing dendritic cells from pluripotent stem cells
GB201103600D0 (en) * 2011-03-01 2011-04-13 Isis Innovation Dendritic cells
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
WO2012135621A2 (en) * 2011-03-30 2012-10-04 Cellular Dynamics International. Inc Priming of pluripotent stem cells for neural differentiation
BR112013030166A2 (pt) * 2011-06-09 2017-03-21 Hoffmann La Roche método de diferenciação de células haste pluripotentes em células leito vasculares, células endoteliais ou células dos músculos moles vasculares, banco biológico e uso de células endoteliais ou células dos músculos moles vasculares, composição terapêutica, métodos e usos.
RU2616281C2 (ru) * 2011-09-29 2017-04-13 СЕЛЛСНЭП, ЭлЭлСи Композиции и способы испытаний на токсикогенность
US20140227780A1 (en) * 2011-10-03 2014-08-14 Nissan Chemical Industries, Ltd. Method for producing megakaryocytes and/or platelets from pluripotent stem cells
CN104053769A (zh) * 2011-11-21 2014-09-17 大学健康网络 造血祖细胞群体和富集其干细胞的方法
HRP20181515T1 (hr) 2011-11-30 2018-11-16 Astellas Institute For Regenerative Medicine Mezenhimne stromalne stanice i upotreba povezana s njima
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US10428309B2 (en) 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
US10273459B2 (en) 2011-12-01 2019-04-30 New York Stem Cell Foundation Automated system for producing induced pluripotent stem cells or differentiated cells
CA2865497A1 (en) * 2012-02-29 2013-09-06 The Johns Hopkins University Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
WO2014011407A2 (en) 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
JP6372782B2 (ja) * 2012-09-28 2018-08-15 公益財団法人神戸医療産業都市推進機構 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法
WO2014079878A1 (en) 2012-11-21 2014-05-30 Merz Pharma Gmbh & Co. Kgaa Means and methods for determination of botulinum neurotoxin biological activity
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
PT2970912T (pt) * 2013-03-13 2019-05-31 Wisconsin Alumni Res Found Métodos e materiais para a diferenciação hematoendotelial de células estaminais pluripotentes humanas em condições definidas
AU2014232381A1 (en) * 2013-03-15 2015-10-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US9994825B2 (en) 2013-03-15 2018-06-12 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US9506037B2 (en) 2013-03-15 2016-11-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
CN105408472A (zh) * 2013-03-15 2016-03-16 马卡斯凯尔·托莱夫·拉尔森 用于脐带血收集及细胞分离的细胞、方法和装置
US9822342B2 (en) 2013-05-14 2017-11-21 Kyoto University Method of efficiently inducing cardiomyocytes
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
US20160146788A1 (en) * 2013-05-23 2016-05-26 Kyoto University Method for screening drugs for treating/preventing myelodysplastic syndrome, etc.
US10119122B2 (en) * 2013-06-10 2018-11-06 Academisch Ziekenhuis Leiden Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures
ES2699432T3 (es) 2013-06-28 2019-02-11 Merz Pharma Gmbh & Co Kgaa Medios y métodos para la determinación de la actividad biológica de polipéptidos de neurotoxinas en células
WO2015050963A1 (en) 2013-10-01 2015-04-09 Manfred Boehm Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings
WO2015119642A1 (en) * 2014-02-10 2015-08-13 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
SG11201606810SA (en) 2014-02-19 2016-09-29 Merz Pharma Gmbh & Co Kgaa Gangliosides for standardizing and increasing the sensitivity of cells to botulinum neurotoxins in in vitro test systems
KR20200138445A (ko) 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
WO2016020288A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
ES2837699T3 (es) 2014-12-19 2021-07-01 Merz Pharma Gmbh & Co Kgaa Medios y métodos para la determinación de la actividad biológica de BoNT/E en células
US10724003B2 (en) 2015-01-16 2020-07-28 Agency For Science, Technology And Research Method of differentiating human pluripotent stem cells into primitive macrophages
US9828634B2 (en) 2015-01-22 2017-11-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
CN114058582A (zh) 2015-01-26 2022-02-18 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
TWI704156B (zh) 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
WO2016187459A1 (en) * 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
EP4026563B1 (en) * 2015-06-18 2025-10-29 Yeda Research and Development Co. Ltd Conditioning protocols and use of same for tissue regeneration
WO2017043604A1 (ja) * 2015-09-08 2017-03-16 大日本住友製薬株式会社 網膜組織の製造方法
CA3002157A1 (en) * 2015-10-20 2017-04-27 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
AU2016343682A1 (en) 2015-10-30 2018-06-14 The Regents Of The University Of California Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
EP3371301A4 (en) 2015-11-04 2019-06-26 Fate Therapeutics, Inc. METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
CN105296428A (zh) * 2015-12-03 2016-02-03 广州医科大学附属第三医院 一种提高诱导多能干细胞的体外分化造血效率的方法
JP6979687B2 (ja) * 2015-12-29 2021-12-15 アイ ピース インク 幹細胞の凝集塊の集団の調製方法
GB201601503D0 (en) 2016-01-27 2016-03-09 Isis Innovation Dendritic cells
DK3460042T3 (da) 2016-05-18 2024-03-11 Univ Keio Celledyrkningsmedium til dyrkning af et organoid, dyrkningsfremgnagsmåde og organoid
JP7039473B2 (ja) * 2016-07-29 2022-03-22 ダイキン工業株式会社 分化細胞の製造方法、及びその製造方法のために使用する培養バッグ
CN109963940A (zh) * 2016-09-02 2019-07-02 宝生物工程株式会社 从多能干细胞获得小胶质细胞的方法
US11525119B2 (en) 2016-09-06 2022-12-13 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
JP7212615B2 (ja) * 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
CN110050061A (zh) * 2016-10-05 2019-07-23 富士胶片细胞动力公司 从具有MeCP2破坏的诱导多能干细胞生成成熟谱系
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN106754684A (zh) * 2017-01-05 2017-05-31 厚朴生物科技（苏州）有限公司 一种睾丸间质干细胞分离培养分化方法
WO2018139600A1 (ja) 2017-01-27 2018-08-02 株式会社カネカ 内胚葉系細胞集団、及び多能性細胞から三胚葉のいずれかの細胞集団を製造する方法
US11932876B2 (en) * 2017-02-03 2024-03-19 Cornell University Stable three-dimensional blood vessels and methods for forming the same
US20200080058A1 (en) * 2017-03-21 2020-03-12 Etablissement Francais Du Sang Methods of improving hematopoietic grafts
EA201992469A1 (ru) 2017-04-18 2020-05-27 Фуджифилм Селльюлар Дайнамикс, Инк. Антигенспецифические иммунные эффекторные клетки
EP3399027A1 (en) 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
CN107083367B (zh) * 2017-07-03 2020-07-14 广州润虹医药科技股份有限公司 培养基及其用途与由尿液细胞制备间充质干细胞的方法
US20200131476A1 (en) * 2017-12-11 2020-04-30 Korea Center For Disease Control And Prevention Differentiation Of Immunocytes Using Pluripotent Stem Cells
WO2019126146A1 (en) 2017-12-19 2019-06-27 Xcell Biosciences, Inc. Methods of modulating cell phenotype by way of regulating the gaseous environment
CN108048390B (zh) * 2017-12-21 2021-04-27 清华大学 一种制备血管内皮细胞的方法及其专用试剂盒
CN108588024B (zh) * 2017-12-29 2020-04-21 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 诱导多能干细胞分化成造血干细胞的培养基及方法
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
IL281413B2 (en) 2018-09-19 2024-09-01 Fujifilm Cellular Dynamics Inc Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
AU2019368313A1 (en) * 2018-10-24 2021-05-20 Hebecell Corporation Methods and systems for manufacturing hematopoietic lineage cells
KR102111441B1 (ko) * 2018-11-12 2020-05-15 대한민국 전분화능 줄기세포 유래 대식세포를 기반으로 하는 감염질환 치료용 약물 스크리닝 방법
US12258583B2 (en) 2018-12-20 2025-03-25 Sumitomo Chemical Company, Limited Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method
JP7634938B2 (ja) * 2019-02-21 2025-02-25 ピービーエス バイオテック インコーポレイテッド バイオリアクターにおける治療細胞の膨張および分化のためのシステムおよび方法
CN111206017B (zh) * 2019-04-30 2022-02-18 浙江大学 一种干细胞无血清培养基及其应用
KR20220032561A (ko) * 2019-06-14 2022-03-15 후지필름 셀룰러 다이내믹스, 인코포레이티드 하전된 표면을 사용하여 유도 만능 줄기 세포로부터 다중 계통을 생산하는 방법
EP3986358A4 (en) 2019-06-20 2023-06-21 Amniotics AB DEVICE FOR FILTERING FRUIT WATER
CN114765957B (zh) 2019-10-18 2025-09-12 Amniotics公司 从羊水中获得羊膜间充质干细胞的方法和设备及其来源的细胞
WO2021096218A1 (ko) * 2019-11-13 2021-05-20 연세대학교 산학협력단 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법
CN110938584B (zh) * 2019-11-25 2021-12-03 广州赛莱拉干细胞科技股份有限公司 一种人胚胎干细胞向内皮细胞诱导分化的方法
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
JOP20220160A1 (ar) 2019-12-20 2023-01-30 Nuevolution As مركبات فعّالة نحو مستقبلات نووية
CN115135754A (zh) * 2020-02-28 2022-09-30 普渡研究基金会 在限定条件下从人多能干细胞生成主动脉-性腺-中肾样造血细胞
US12220445B2 (en) 2020-03-09 2025-02-11 Amprion, Inc. Inert matrices for qualitative and semi-quantitative seed amplification assays
CN111440760B (zh) * 2020-03-09 2022-09-23 浙江大学 一种人多能干细胞高效分化得到内皮祖细胞的方法
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
CN115885038A (zh) 2020-06-17 2023-03-31 国立大学法人京都大学 表达嵌合抗原受体的免疫活性细胞
CN116096858A (zh) * 2020-07-27 2023-05-09 加拿大干细胞技术公司 用于分化造血细胞的系统和方法
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
CN112608895B (zh) * 2020-12-18 2024-02-27 深圳市济因生物科技有限公司 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
AU2022253223A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
MX2023011927A (es) 2021-04-07 2023-10-23 Century Therapeutics Inc Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
US20220331361A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
JP2024516992A (ja) 2021-05-05 2024-04-18 フジフィルム セルラー ダイナミクス，インコーポレイテッド Ｉｐｓｃ由来ミクログリアのための方法及び組成物
CA3231278A1 (en) 2021-09-10 2023-03-16 Deepika Rajesh Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
EP4402164A4 (en) * 2021-09-13 2025-07-02 Amprion Inc INERT MATRICES FOR QUALITATIVE AND SEMI-QUANTITATIVE SEED AMPLIFICATION ASSAYS
WO2023110045A1 (en) 2021-12-15 2023-06-22 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation
JP2025501214A (ja) 2021-12-29 2025-01-17 センチュリー セラピューティクス，インコーポレイテッド 抗ｃｄ１９／抗ｃｄ２２キメラ抗原受容体を有する遺伝子操作細胞、およびその使用
AU2023223404A1 (en) 2022-02-22 2024-08-29 Juno Therapeutics, Inc. Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
JP2025515095A (ja) 2022-05-04 2025-05-13 センチュリー セラピューティクス，インコーポレイテッド Ｈｌａ－ｅおよびｈｌａ－ｇ導入遺伝子を用いて操作された細胞
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
JP2025537284A (ja) 2022-11-10 2025-11-14 センチュリー セラピューティクス，インコーポレイテッド 抗ネクチン４キメラ抗原受容体を有する遺伝子操作細胞、およびその使用
US20240269189A1 (en) 2022-12-19 2024-08-15 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
AU2024223390A1 (en) * 2023-02-16 2025-08-28 Syntax Bio, Inc. Systems for cell programming towards hematopoietic lineage and methods thereof
CN116426472A (zh) * 2023-06-08 2023-07-14 呈诺再生医学科技(北京)有限公司 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583287D1 (de) 1984-12-27 1991-07-25 Asahi Chemical Ind Substituierte isochinolinsulfonyl-verbindungen.
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
JP2001508302A (ja) * 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
HK1042656A1 (en) 1999-03-25 2002-08-23 三菱制药株式会社 Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
EP1367899A4 (en) * 2001-02-14 2004-07-28 Leo T Furcht TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
CN1630716A (zh) * 2001-12-07 2005-06-22 杰龙公司 人胚胎干细胞衍生的造血细胞
ATE464373T1 (de) * 2001-12-21 2010-04-15 Mount Sinai Hospital Corp Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
ATE381557T1 (de) 2002-01-23 2008-01-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
CA2482598C (en) * 2002-04-22 2012-09-25 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
US7723106B2 (en) * 2004-07-29 2010-05-25 Food Industry Research & Development Institute Stroma-free, serum-free, and chemically defined medium and method for ex vivo mononuclear cell expansion using the same
BRPI0508594A (pt) 2004-03-08 2007-08-21 Wyeth Corp moduladores de canal de ìon
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
WO2006029197A1 (en) * 2004-09-08 2006-03-16 Wisconsin Alumni Research Foundation Medium and culture of embryonic stem cells
US20070077654A1 (en) * 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells
MX2007005200A (es) 2004-11-01 2007-05-11 Wisconsin Alumni Res Found Plaquetas a partir de celulas germinales.
JP4964121B2 (ja) 2005-02-23 2012-06-27 財団法人先端医療振興財団 血管内皮前駆細胞の生体外増幅方法
AU2006318327B2 (en) * 2005-11-28 2011-08-18 Choongwae Pharma Corporation Serum-free expansion of cells in culture
JP2008099662A (ja) * 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
US20110151554A1 (en) * 2006-11-09 2011-06-23 Akira Yuo Method for culturing and subculturing primate embryonic stem cell, as well as method for inducing differentiation thereof
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
AU2009228215B2 (en) * 2008-03-27 2015-12-10 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
JP5632831B2 (ja) * 2008-05-02 2014-11-26 セルラー ダイナミクス インターナショナル， インコーポレイテッド 幹細胞からの肥満細胞の生産のための方法
US20110263016A1 (en) * 2008-09-25 2011-10-27 Rancourt Derrick E Expansion of Embryonic Stem Cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Park, C. et al., DEVELOPMENT, June 2004, 131(11):2749-2762

Also Published As

Publication number Publication date
IL214818A0 (en) 2011-11-30
WO2010099539A1 (en) 2010-09-02
JP2012519005A (ja) 2012-08-23
US8372642B2 (en) 2013-02-12
JP5816100B2 (ja) 2015-11-18
US20130210141A1 (en) 2013-08-15
US10100282B2 (en) 2018-10-16
AU2010217739B2 (en) 2015-09-03
CN102388130B (zh) 2014-08-27
EP2401364A1 (en) 2012-01-04
IL214818A (en) 2014-07-31
CA2753679A1 (en) 2010-09-02
CN102388130A (zh) 2012-03-21
US20100279403A1 (en) 2010-11-04
EP2401364B1 (en) 2015-04-22
JP2015192681A (ja) 2015-11-05
KR20110122858A (ko) 2011-11-11
AU2010217739A1 (en) 2011-09-08
CA2753679C (en) 2021-03-02

Similar Documents

Publication Publication Date Title
KR101720961B1 (ko) 다능성 세포의 분화
JP2012519005A5 (enExample)
JP6189581B2 (ja) 幹細胞の分化のための方法および組成物
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
EP3282010A1 (en) Methods for producing enucleated erythroid cells derived from pluripotent stem cells
JP2023536125A (ja) 造血細胞を分化させるシステム及び方法
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20200218

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10